2006 - A Very Good Year in MS Research

NEW YORK, Dec. 7 /PRNewswire/ -- During 2006, rapid research progress was made in the fields of science and medicine that impact understanding and treatment of multiple sclerosis, an unpredictable neurological disease. The National MS Society invested over $42 million this year to support more than 350 new and ongoing MS research projects as part of its international efforts around collaborative and cutting-edge research.

Significant advances have been made in both clinical and laboratory studies in MS. In addition, more than 130 clinical trials are underway around the world, and still other experimental drugs are in the pipeline. Key highlights of the year include:

  * Acorda Therapeutics (Hawthorne, NY) announced positive results of a
    Phase 3, placebo-controlled clinical trial of Fampridine-SR, an oral
    drug designed to provide symptomatic relief by compensating for lost
    nerve conduction.  In 301 patients with all types of MS, those on active
    treatment showed an average increase in walking speed of 25% versus
    those on inactive placebo.  The company is expected to meet with the
    U.S. Food and Drug Administration (FDA) to determine next steps needed
    to apply for marketing approval.

  * The FDA approved the return to market of Tysabri(R) (natalizumab,
    produced by Biogen Idec and Elan Pharmaceuticals) to delay the
    accumulation of physical disability and reduce the frequency of relapses
    (clinical exacerbations) in those with relapsing MS.  There is now in
    place a mandatory registration program for patients and prescribing
    physicians to minimize the risk of PML (progressive multifocal
    leukoencephalopathy), caused by a common virus called the JC virus.  The
    drug is dispensed at registered infusion centers across the country.
    Since Tysabri's return to market last summer, there have been no new
    cases of PML reported.

  * Members of the four Nervous System Repair teams from Europe and the U.S.
    met to share progress being made in the Society funded Promise: 2010
    initiative.  The first clinical trials focused on protecting the nervous
    system will begin shortly, and trials aimed at repairing damage and
    restoring function in people with MS are expected to begin within the
    next five years.

  * In a first, Johns Hopkins University researchers reported that nerve
    cells derived from mouse embryonic stem cells that were transplanted
    into rats with spinal cord injury were able to connect with muscles and
    partially restore function.  While this work was done in a model of
    spinal cord injury, it bears relevance to the potential use of cell
    replacement to repair damage in MS.

  * The Society will be sponsoring the first ever stem cell summit January
    16-19 in San Francisco to explore the potential of the complete spectrum
    of stem cell options as they might relate to MS research and treatment.
    The by-invitation only meeting will bring together some 60 renowned
    scientists from around the world to examine stem cell prospects and
    strategies in MS.  The results of this meeting are expected to set
    research directions and priorities to best determine the potential of
    all types of stem cells for treating this disease.

  * Researchers from the University of California, Los Angeles reported that
    administering Androgel(R) (testosterone gel applied to the skin) to 10
    men with relapsing-remitting MS significantly improved cognitive
    function and slowed brain tissue loss.  This study was funded by the
    Society's initiative on Gender Differences in MS and is expected to lead
    to additional research involving larger numbers of patients to confirm
    these early results.

  * In another offshoot from the Society's initiative on Gender Differences,
    UCLA investigators began the first large-scale trial of a sex hormone
    for the treatment of MS.  The two-year, controlled clinical trial of
    estriol involves 130 women with early relapsing-remitting MS.  If
    successful, this clinical trial will lay the groundwork for a larger,
    definitive trial that could lead to a new treatment option for women
    with MS.  Its results may also have implications for women with other
    autoimmune diseases, such as rheumatoid arthritis.

  * Several oral MS therapies continued to progress through the pipeline:

    -- a phase II controlled clinical trial of oral fingolimod (FTY720,
       Novartis Pharmaceuticals Corp.) in 255 people with active, relapsing
       MS found that up to 77% of those taking fingolimod remained free of
       relapses over two years; a large phase III trial is now underway;

    -- oral cladribine (an immune-modulating drug by Serono), now being
       tested in an international Phase 3 clinical trial, has been
       designated by the FDA as a "Fast Track Product," which should
       expedite its future review;

    -- a multicenter, phase II controlled clinical trial of oral BG00012 (an
       oral fumarate, Biogen Idec) led to a 69% reduction in active
       inflammation on MRI scans in 257 people with relapsing-remitting MS;

    -- in an open-label, 144-week extension study of oral teriflunomide (an
       agent that may modulate T cells), those on placebo during the
       original trial who switched to teriflunomide experienced up to an 85%
       decrease in new, active areas of disease activity seen on MRI at week
       144.

  * Harvard investigators reported that individuals who showed signs of
    significant exposure to the Epstein-Barr virus, which causes infectious
    mononucleosis and other disorders, were twice as likely to develop MS up
    to 20 years later.  The study, funded in part by a grant from the
    National MS Society, adds to previous evidence linking the virus to the
    risk of developing MS, but does not prove that EBV actually causes MS.
    Other recent studies have suggested that smoking cigarettes may
    contribute to the risk of MS and MS progression, and that higher vitamin
    D intake may help protect against developing MS.

  * For the first time, the needs of children who develop MS-like symptoms
    are being addressed through the Society's nationwide network of
    comprehensive Pediatric MS Centers of Excellence, launched early this
    year.  The 6 centers have committed to sharing critical resources and
    best practices such as MRI protocols and neuropsychological evaluations
    so that all families can benefit from the collective knowledge of the
    entire network.  In addition to providing optimal care and support,
    these centers will build a framework for research into this patient
    population, which may also provide clues to adult MS.

  * Two genes that may contribute to making a person susceptible to
    developing MS have been identified by a group of European researchers
    known as the "GAMES" Collaborative Group.  MS involves an immune-system
    attack on the body's own brain and spinal cord, and many genes are
    thought to contribute to susceptibility.  The two candidate genes were
    singled out because they encode for a brain tissue component and an
    immune component.  This work was supported in part by the National MS
    Society.

  * Researchers at Stanford University have uncovered evidence they believe
    may explain the role of a protein, osteopontin, in stimulating repeated
    relapses and disease progression as well as inhibiting spontaneous
    recovery from symptoms.  This research, sponsored in part by the
    Society, could lead to new therapeutic approaches that target
    oseopontin's effect in the MS disease process.

  * The National MS Society launched a new postdoctoral fellowship program
    in MS rehabilitation research.  The immediate goal is to recruit and
    train talented clinician-scientists in rehabilitation research specific
    to MS; the ultimate goal is to get more hands and minds working on ways
    to help people with MS maximize their abilities.


  About Multiple Sclerosis

Multiple sclerosis interrupts the flow of information from the brain to the body and stops people from moving. Every hour in the United States, someone is newly diagnosed with MS, an unpredictable, often disabling disease of the central nervous system. Symptoms range from numbness and tingling to blindness and paralysis. The progress, severity and specific symptoms of MS in any one person cannot yet be predicted, but advances in research and treatment are moving us closer to a world free of MS. Most people with MS are diagnosed between the ages of 20 and 50, with more than twice as many women as men being diagnosed with the disease. MS affects more than 400,000 people in the U.S., and 2.5 million worldwide.

About the National Multiple Sclerosis Society

MS stops people from moving. The National MS Society exists to make sure it doesn't. We help each person address the challenges of living with MS through our 50 state network of chapters. We fund more MS research, provide more services to people with MS, offer more professional education and further more advocacy efforts than any other MS organization in the world. The Society is dedicated to achieving a world free of MS. We are people who want to do something about MS now. Join the movement at http://www.nationalmssociety.org/.

Studies show that early and ongoing treatment with an FDA-approved therapy can reduce future disease activity and improve quality of life for many people with multiple sclerosis. Talk to your health care professional and contact the National MS Society at http://www.nationalmssociety.org/ or 1-800-344-4867 to learn about ways to help manage multiple sclerosis and about current research that may one day reveal a cure.